MetaCap

Allogene Therapeutics Inc. (ALLO)

NASDAQ: ALLOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

0.6277-0.0392 (-5.88%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ALLO stock chart

Technical analysis

Key statistics

All statistics
Market cap
$217.48M
EPS (TTM)
-$0.61
52-week range
0.6192 – 4.46
Day range
0.6192 – 0.67
Volume / Avg
7.57M / 7.69M
Beta
—

52-week range

$0.6192$4.46

ALLO stock today

Allogene Therapeutics (ALLO) closed at $0.6277 on Nov 20, down 5.88% (-$0.0392), versus the S&P 500's 3.70% decline. At this level, ALLO sits near the bottom of its 52-week range of $0.6192 to $4.46: 85.9% below the high, set on Apr 13, 2026 and 1.4% above the low. ALLO is down 54.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 49.0%.

Allogene Therapeutics has posted a net loss over the last twelve months (EPS of -$0.61), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Allogene Therapeutics

Company profile

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Zachary J. Roberts M.D., Ph.D.
Headquarters
South San Francisco, CA
Employees
150
IPO year
2018

Financial highlights

Full financials

In fiscal 2025, Allogene Therapeutics generated $0 in revenue, down 100.0% from fiscal 2024, its first annual decline since 2024. Allogene Therapeutics reported a net loss of $190.9 million, compared with a loss of $257.6 million a year earlier. Diluted earnings per share came in at -$0.87.

Allogene Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$0$22.00K$95.00K$156.00K$114.09M
Growth-100.00%-76.84%-39.10%-99.86%—
Net income$-190.89M$-257.59M$-327.26M$-340.41M$-182.05M
EPS (diluted)$-0.87$-1.32$-2.09$-2.38$-1.34

Analyst forecast

Forecast

Consensus (12 analysts)

strong_buy

Avg. price target

$9.00+1333.81%

  • Strong buy 3
  • Buy 8
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $4.00High $14.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.19 vs $-0.13
Surprise
-46.15%

ALLO news

All ALLO news

Allogene Therapeutics peers

Health Care sector
ALLO peer companies
CompanyPrice% ChgMarket capCompare
IPSCCentury Therapeutics Inc.1.17-11.74%$211.56Mvs ALLO
SCTXScribe Therapeutics Inc.12.07-8.70%$228.58Mvs ALLO
CABACabaletta Bio Inc.0.9361-7.32%$201.94Mvs ALLO
LCTXLineage Cell Therapeutics Inc.0.7719-5.87%$195.26Mvs ALLO
AUTLAutolus Therapeutics plc ADR0.9073-7.38%$241.65Mvs ALLO
PLXProtalix BioTherapeutics Inc. (DE)2.90-5.23%$244.52Mvs ALLO
LXEOLexeo Therapeutics Inc.2.96+0.34%$245.05Mvs ALLO
ARTVArtiva Biotherapeutics Inc.3.78-1.31%$186.85Mvs ALLO

Indexes, lists and sector

Allogene Therapeutics stock FAQ

What is Allogene Therapeutics's stock price today?

ALLO last traded at $0.6277 as of Nov 20, 4:00 PM EST, down 5.88% on the day. Prices are delayed at least 15 minutes.

Who is Allogene Therapeutics's CEO?

Dr. Zachary J. Roberts M.D., Ph.D. is the chief executive officer of Allogene Therapeutics Inc., which has about 150 employees.

What is the ALLO 52-week high?

The 52-week high for ALLO is $4.46 and the 52-week low is $0.6192. The stock is currently 85.9% below its high.

Compare ALLO